Answers are grounded in this paper and cite their sources.
Decision modeling shows enhanced protection against RSV in infants, suggesting a need for combined immunization strategies.
A complementary strategy with maternal RSVpreF vaccination and nirsevimab immunization for otherwise unprotected and preterm infants in Germany would provide a greater benefit compared to nirsevimab alone, protecting substantially more infants at lower total costs.
No takes yet. Share an insight, caveat, or question.
Lade et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: